Int J Clin Exp Pathol 2015;8(5):5642-5649 www.ijcep.com /ISSN:1936-2625/IJCEP0006771
Original Article Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma Phui-Ly Liew1,2, Chun-Sen Hsu3, Wei-Min Liu4, Yu-Chieh Lee5, Yi-Chih Lee6, Chi-Long Chen2,7 Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan; 2Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 3Department of Obstetrics and Gynecology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; 4Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan; 5Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan; 6Department of International Business, Chien Hsin University of Science and Technology, Zhongli City, Taiwan; 7Department of Pathology, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan 1
Received February 6, 2015; Accepted April 9, 2015; Epub May 1, 2015; Published May 15, 2015 Abstract: Objectives: Despite considerable interest in the Nuclear factor-erythroid 2-related factor 2 (Nrf2)/Kelchlike ECH-associated protein-1 (Keap1), p16 and epithelial cadherin (E-cadherin) activation in carcinoma progression, contradictory results regarding association of Nrf2/Keap1/E-cadherin and p16 expression with clinico-pathological features and prognosis have been reported. The predictive value of these markers in ovarian carcinoma is unknown. Methods/Materials: In this retrospective study, 108 cases were evaluated immunohistochemically with antibodies to Nrf2, Keap1, estrogen receptor (ER), p16 and E-cadherin. The results were compared with histological and clinical data, disease-free survival (DFS) and overall survival (OS). Results: A cohort of 108 ovarian carcinomas (47 serous, 23 mucinous, 13 endometrioid and 25 clear cell), including 68 FIGO stage I-II cases and 40 FIGO stage III-IV cases was studied. The age of patients (P=0.005), FIGO stage (P
Original Article Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma Phui-Ly Liew1,2, Chun-Sen Hsu3, Wei-Min Liu4, Yu-Chieh Lee5, Yi-Chih Lee6, Chi-Long Chen2,7 Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan; 2Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 3Department of Obstetrics and Gynecology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; 4Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan; 5Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan; 6Department of International Business, Chien Hsin University of Science and Technology, Zhongli City, Taiwan; 7Department of Pathology, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan 1
Received February 6, 2015; Accepted April 9, 2015; Epub May 1, 2015; Published May 15, 2015 Abstract: Objectives: Despite considerable interest in the Nuclear factor-erythroid 2-related factor 2 (Nrf2)/Kelchlike ECH-associated protein-1 (Keap1), p16 and epithelial cadherin (E-cadherin) activation in carcinoma progression, contradictory results regarding association of Nrf2/Keap1/E-cadherin and p16 expression with clinico-pathological features and prognosis have been reported. The predictive value of these markers in ovarian carcinoma is unknown. Methods/Materials: In this retrospective study, 108 cases were evaluated immunohistochemically with antibodies to Nrf2, Keap1, estrogen receptor (ER), p16 and E-cadherin. The results were compared with histological and clinical data, disease-free survival (DFS) and overall survival (OS). Results: A cohort of 108 ovarian carcinomas (47 serous, 23 mucinous, 13 endometrioid and 25 clear cell), including 68 FIGO stage I-II cases and 40 FIGO stage III-IV cases was studied. The age of patients (P=0.005), FIGO stage (P
